Pages that link to "Q35914452"
Jump to navigation
Jump to search
The following pages link to Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo (Q35914452):
Displaying 50 items.
- Adeno-associated Virus as a Mammalian DNA Vector (Q26782605) (← links)
- Animal models of hemophilia (Q27012571) (← links)
- Progress and prospects: immune responses to viral vectors (Q28264531) (← links)
- AAV's anatomy: roadmap for optimizing vectors for translational success (Q33659389) (← links)
- Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle (Q33713019) (← links)
- A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer (Q33713730) (← links)
- The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques (Q33730459) (← links)
- Influence of immune responses in gene/stem cell therapies for muscular dystrophies (Q33736192) (← links)
- Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice (Q33792012) (← links)
- Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions (Q33938435) (← links)
- Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them. (Q34370111) (← links)
- Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice. (Q34621723) (← links)
- Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brain (Q34718452) (← links)
- AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes (Q36106408) (← links)
- Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles (Q36171820) (← links)
- An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8+ T Cells (Q36365372) (← links)
- Adeno-associated virus capsid antigen presentation is dependent on endosomal escape (Q36638203) (← links)
- Evading the immune response upon in vivo gene therapy with viral vectors. (Q36644230) (← links)
- Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. (Q36709834) (← links)
- Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical (Q36848699) (← links)
- IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression (Q36976498) (← links)
- Immune responses to AAV vectors: overcoming barriers to successful gene therapy (Q36983740) (← links)
- Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy (Q37066228) (← links)
- Immunity to adeno-associated virus vectors in animals and humans: a continued challenge (Q37127246) (← links)
- AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects (Q37146095) (← links)
- A small regulatory element from chromosome 19 enhances liver-specific gene expression (Q37148191) (← links)
- Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors (Q37209197) (← links)
- Cellular immune response to cryptic epitopes during therapeutic gene transfer (Q37250034) (← links)
- Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy (Q37277411) (← links)
- The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice (Q37286686) (← links)
- Tailoring the AAV vector capsid for gene therapy. (Q37340302) (← links)
- Transient transfection methods for clinical adeno-associated viral vector production (Q37479802) (← links)
- Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model (Q37686976) (← links)
- Gene therapy strategies for hemophilia: benefits versus risks (Q37789715) (← links)
- Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges (Q37866086) (← links)
- Targeted Gene Therapy for the Treatment of Heart Failure (Q37878086) (← links)
- Manipulating Immune Tolerance with Micro-RNA Regulated Gene Therapy. (Q37965158) (← links)
- Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors (Q38191212) (← links)
- The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer (Q38539938) (← links)
- Continuous CD8⁺ T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery (Q38959186) (← links)
- Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses (Q39501488) (← links)
- Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia (Q39519818) (← links)
- Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia (Q39553052) (← links)
- Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo (Q39860625) (← links)
- Gene delivery to the juvenile mouse liver using AAV2/8 vectors (Q39991575) (← links)
- Unraveling the complex story of immune responses to AAV vectors trial after trial (Q40073271) (← links)
- Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes (Q41907025) (← links)
- Gene therapy for hemophilia: the clot thickens. (Q42184386) (← links)
- Gene Therapy for Hemophilia: Progress to Date. (Q45874307) (← links)
- Emerging Issues in AAV-Mediated In Vivo Gene Therapy (Q47554736) (← links)